GCG and type 2 diabetes mellitus: Dipeptidyl peptidase‐4 (DPP‐4) inhibitors, which suppress degradation of the incretins glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to potentiate insulin secretion glucose‐dependently, are therefore in wide use today in the management of type 2 diabetes in Asia1, 2.